The novel combination treatment of pembrolizumab chemotherapy and oncolytic adenovirus therapy offers hope for immunotherapy-resistant non-muscle-invasive bladder cancer patients, potentially avoiding high-risk bladder removal surgery.
Bladder cancer, particularly non-muscle-invasive cases, presents a significant health challenge, with the need for alternative treatments beyond surgery and BCG immunotherapy.
CG0070, an engineered oncolytic adenovirus, may provide a promising non-invasive treatment approach for patients with non-muscle-invasive bladder cancer who do not respond to standard therapies.
[
Collection
]
[
|
...
]